Abstract
ObjectiveThe ASTRUM-005 trial showed that serplulimab plus chemotherapy (SEP) significantly extended survival time compared with chemotherapy in the treatment of small cell lung cancer. But the survival benefits of SEP...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have